logo
Brian Greene Tells LMU Graduates: Embrace Your Moment in the Cosmos with Curiosity and Gratitude

Brian Greene Tells LMU Graduates: Embrace Your Moment in the Cosmos with Curiosity and Gratitude

Yahoo18-05-2025

LOS ANGELES, May 18, 2025 /PRNewswire/ -- Brian Greene, a leading theoretical physicist and sought-after communicator of groundbreaking scientific concepts, urged those gathered Sunday for Loyola Marymount University's graduate and LMU Loyola Law School commencement to appreciate their unique existence in the cosmos, embrace their potential, and approach life with gratitude.
Addressing a rapt crowd on LMU's sun-filled Westchester campus, the best-selling author told graduates "we have each won the most improbable cosmic lottery." See the press kit with images and Greene's commencement video HERE.
"Think about how utterly unlikely it is that you exist," Greene said. "Think about the nearly infinite collection of quantum processes stretching from The Big Bang until today … yet against those astounding odds – for a brief moment of time you exist, as do I."
Drawing on discoveries from Albert Einstein to Stephen Hawking and Carl Sagan to Edwin Hubble, Greene traced for students and attendees the arc of scientific discovery allowing us to better understand our place in the universe, and the phenomenon of our capacity to live, comprehend, and connect with one another. Greene also noted the contributions of Jesuit-educated Catholic priest Georges Lemaître, who "used Einstein's math to catch a glimpse of the possibility that space might be expanding," an idea widely rejected at the time, only to be established a few years later.
"We can think about the past. We can imagine the future. We can take in the universe, mind and body, with reasoning and emotion allowing us to figure out astonishing things, like how stars shine and light travels, how black holes form and time elapses, allowing for creative achievements … all created by minds like yours, like mine, and that …most certainly will continue to create great beauty, to illuminate great mystery, to experience great wonder."
This phenomenon of human existence, Greene concluded, "should give us all a deep sense of connection. A kind of cosmic communion, and a sense that I can summarize with one word: gratitude."
"Gratitude for being a small transient part of this wondrous unfolding, gratitude for our capacity to come together in groups that, at their best, allow us to each realize our potential, gratitude for our capacity for courage like that of George Lemaître, to stand up to authority, to not accept easy answers, and when necessary to fight for what we believe in. Gratitude that is for human existence, for fragile, delicate, difficult, challenging, painful, exhausting, beautiful, exquisite, transcendent, human existence, however brief, however evanescent, however fleeting."
Greene is a lifelong learner committed to intellectual inquiry, educational access, and academic excellence. Described by The Washington Post as "the single best explainer of abstruse concepts in the world today," he is the author of four acclaimed books that have collectively sold millions of copies worldwide. His latest best-selling release, "Until the End of Time," which explores the cosmos and our quest to understand it, was named one of the "100 Notable Books of 2020" by The New York Times.
Greene's books have been adapted into two Emmy and Peabody Award-winning NOVA miniseries, both of which he hosted. With journalist Tracy Day, he co-founded the World Science Festival, whose flagship events in New York and Australia have reached an audience of more than two million people, and more than 250 million people online. Greene has appeared on "The Late Show with Stephen Colbert," played himself in an episode of "The Big Bang Theory," and made cameo appearances in films including "Frequency," "Maze," and "The Last Mimzy." A Harvard graduate and a Rhodes Scholar, he serves as director of Columbia University's Center for Theoretical Physics.
Nearly 2,900 LMU undergraduate, graduate, and law students participated in weekend commencement celebrations, which began Saturday with Ahmir "Questlove" Thompson addressing the undergraduate commencement ceremony.
ABOUT LOYOLA MARYMOUNT UNIVERSITY
Loyola Marymount University is one of the nation's top-ranked Catholic universities, recognized by U.S. News & World Report among the top 50 private and top five Jesuit institutions in the country, and among California's top six private schools. Founded in 1911 and rooted in the Catholic, Jesuit, and Marymount traditions, LMU enrolls 7,100 undergraduates and 3,000 graduate and law students across seven colleges and schools. The university offers 56 undergraduate majors, 57 minors, 43 master's degree programs, three doctorate programs, and 12 credential/authorization programs. With top-ranked programs in law, film and television, entrepreneurship, business, and the arts, LMU is embedded in the creative, cultural, and economic life of Los Angeles. The university generates $1.4 billion in annual economic impact. A proud member of the West Coast Conference, LMU fields 14 NCAA Division I teams and competes with purpose, pride, and integrity.
LMU news and events are found at: www.lmu.edu/news.
View original content to download multimedia:https://www.prnewswire.com/news-releases/brian-greene-tells-lmu-graduates-embrace-your-moment-in-the-cosmos-with-curiosity-and-gratitude-302458502.html
SOURCE Loyola Marymount University

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Domino Data Lab Named a Visionary for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Data Science and Machine Learning Platforms
Domino Data Lab Named a Visionary for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Data Science and Machine Learning Platforms

Yahoo

time36 minutes ago

  • Yahoo

Domino Data Lab Named a Visionary for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Data Science and Machine Learning Platforms

Domino continues to differentiate with enterprise-grade AI governance, hybrid cloud orchestration, and generative AI innovation — trusted by the most regulated industries SAN FRANCISCO, May 30, 2025 /PRNewswire/ -- Domino Data Lab, provider of the leading Enterprise AI Platform trusted by the largest AI-driven companies, has been named a Visionary in the 2025 Gartner® Magic Quadrant™ for Data Science and Machine Learning Platforms. This marks the second consecutive year that Domino has been recognized as a Visionary. The Magic Quadrant Report evaluated 16 vendors based on their Completeness of Vision and Ability to Execute, with Domino being positioned in the Visionaries Quadrant amongst other vendors. For Domino, this consistent recognition underscores the company's role as a strategic partner for highly regulated enterprises navigating the rapidly evolving AI landscape. We believe it signals sustained market momentum and a reliable, forward-looking, trusted approach used consistently by customers to solve the most complex life sciences, financial services, public sector, and insurance challenges. "Enterprises trust Domino to move faster, reduce risk, and deliver real-world AI impact," said Nick Elprin, co-founder and CEO of Domino Data Lab. "In our opinion, the Gartner recognition of Domino as a Visionary for the second year running reinforces what our customers already know: we help them cut time to AI value, streamline governance, and scale mission-critical AI." Validated Innovation and Strategic Relevance To the company, this milestone marks a significant step in Domino's track record of anticipating enterprise AI needs — from open architecture and hybrid infrastructure to governance and cost control. As enterprises scale AI amidst rising regulatory and operational risks, Domino's strengths in MLOps, rigorous control over AI quality, and FinOps help teams move from pilot to production with confidence. Trusted by leaders in life sciences, financial services, and the public sector — and rated 4.5/5 on Gartner Peer Insights™ (as of 08 May 2025 based on 124 ratings) — Domino is the strategic choice for regulated enterprises seeking to lead with innovation and future-proof their AI investments. Continuous Innovation Across the AI Lifecycle Since its 2024 recognition, Domino has introduced a series of breakthrough platform capabilities, reinforcing its differentiation as the only unified system for developing and governing AI across any infrastructure: Domino Governance – The industry's first built-in governance solution that automates policy enforcement and evidence collection throughout the AI lifecycle, reducing validation timelines by up to 70% for use cases like model risk management and statistical computing in life sciences. Support for NVIDIA NIM™ microservices – Enables seamless deployment of GenAI workloads with enhanced performance and built-in governance across hybrid environments. Domino Volumes for NetApp ONTAP (DVNO) – Delivers fast, compliant access to enterprise data across clouds and on-premises systems, cutting AI data processing time by up to 50% while preserving full traceability. Model deployment to Amazon SageMaker – Gives AI teams greater flexibility to run inference workloads cost-effectively in public cloud environments without leaving the Domino platform. These capabilities are integrated within the Domino Nexus architecture, which provides a unified control plane across multi-cloud and on-premises environments. With this flexibility, global enterprises can run AI wherever data resides — enabling performance, compliance, and cost efficiency at scale. Trusted by the Most Regulated Enterprises Domino continues to expand its footprint in sectors such as life sciences, financial services, insurance, and the public sector, where auditability, compliance, and data locality are mission-critical. Over the past fiscal year, Domino Cloud's annual recurring revenue in the life sciences grew by more than 12X, driven by rapid adoption of its managed SaaS solution that supports GxP, HIPAA, and other regulatory standards. Access the 2025 Gartner Magic Quadrant Gartner clients can access the full 2025 Gartner Magic Quadrant for Data Science and Machine Learning Platforms at: Gartner Disclaimer Gartner, Magic Quadrant for Data Science and Machine Learning Platforms, 28 May 2025, Afraz Jaffri Et Al. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. About Domino Data LabDomino Data Lab empowers the largest AI-driven enterprises to build and operate AI at scale. Domino's Enterprise AI Platform provides an integrated experience encompassing model development, MLOps, collaboration, and governance. With Domino, global enterprises can develop better medicines, grow more productive crops, develop more competitive products, and more. Founded in 2013, Domino is backed by Sequoia Capital, Coatue Management, NVIDIA, Snowflake, and other leading investors. Learn more at View original content to download multimedia: SOURCE Domino Data Lab Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

Associated Press

timean hour ago

  • Associated Press

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

BOSTON, May 30, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy volunteers (HV) in its clinical trial for BBT002, a novel, half-life extended bispecific antibody designed as a 'platform in a molecule' with broad applications across respiratory, dermatology, and gastroenterology. The Phase 1 clinical trial (BBT002-001; NCT06944925 ) is a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study evaluating BBT002 in healthy volunteers and adults with COPD. The study will evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of BBT002. Approximately 96 participants are expected to enroll across multiple sites. Interim safety and pharmacokinetic data are anticipated in the first quarter of 2026. Bambusa is also considering expanding into additional indications including asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and food allergy, to fully realize the 'platform-in-a-molecule' potential for BBT002. 'Advancing our second program into the clinic within just 12 months of founding Bambusa reflects the speed, precision, and high standards that define our development culture,' said Thang Ho, PhD, Senior Vice President of Development Sciences at Bambusa Therapeutics. 'BBT002's dual-target mechanism leverages two of the most classic and fundamental inflammatory pathways—enabling a rational, biology-driven approach to push the efficacy ceiling beyond what single-target therapies can achieve. We believe this strategy may offer additive or synergistic benefit, particularly for patients with complex, multi-organ inflammatory diseases. This milestone highlights our team's ability to rapidly translate bold science into clinical-stage programs with broad impact.' Separately, Bambusa also announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to proceed with the clinical development of BBT001, a novel multi-targeting, half-life extended bispecific antibody for the treatment of atopic dermatitis and other inflammatory skin diseases. BBT001 is currently being studied in a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study conducted in Australia, evaluating BBT001 in healthy volunteers and adults with moderate to severe atopic dermatitis. About Bambusa's pipeline BBT001 is a novel half-life extended bispecific antibody. Preclinical data with BBT001 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics in atopic dermatitis. It is currently being tested in a Phase I clinical study (BBT001-001; NCT06808477) BBT002 is a novel half-life extended bispecific antibody designed as a 'platform in a molecule' with broad applications across respiratory, dermatology, and gastroenterology indications. Preclinical data with BBT002 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics across multiple inflammatory conditions. It is currently being tested in a Phase I clinical study (BBT002-001; NCT06944925 ). The company's additional pipeline candidates, BBT003 and BBT004, are being developed for inflammatory bowel disease and rheumatological conditions, each with best-in-disease potential. About Bambusa Therapeutics Bambusa Therapeutics is a clinical-stage biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa's mission is to advance the field of immunology with cutting-edge solutions. For more information, visit View original content to download multimedia: SOURCE Bambusa Therapeutics

Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting

Yahoo

timean hour ago

  • Yahoo

Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting

FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting results of two studies demonstrating the ability of its MRD test to predict progression and identify non-responders to immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 – June 3, 2025. "In patients with advanced cancer receiving immunotherapy, it can be challenging to differentiate true progression from pseudoprogression during early treatment cycles based on imaging," said Lillian Siu, MD, FRCPC, Medical Oncologist and Senior Scientist, Princess Margaret Cancer Centre, University Health Network. "To better identify non-responders and guide timely treatment adjustments, more reliable response assessment tools are needed. Methylation-based circulating tumor DNA (ctDNA) technology shows promise in these regards." The ability of Adela's test to identify progression in patients treated with immunotherapy was demonstrated in two studies. The first study included banked samples from 64 patients with advanced head & neck, breast, ovarian, melanoma, or other solid tumors who received pembrolizumab. Blood samples were collected pre-treatment and prior to initiation of cycle 3 of treatment. A decrease in ctDNA from the pre-treatment blood draw to the pre-cycle 3 blood draw was associated with a significantly better PFS [hazard ratio (HR) of 0.28 (0.15, 0.49); p<0.0001] and OS [HR 0.42 (0.24, 0.76); p=0.003]. "These results show promise in assessing response to immunotherapy early in a patient's course of treatment," said Enrique Sanz-Garcia, MD, Medical Oncologist and Clinician-Investigator at Princess Margaret Cancer Centre, University Health Network. "Identifying non-response earlier can support timely treatment decisions and help avoid unnecessary toxicity." The second study included banked samples from 63 patients with stage III/IV non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab (stage III) or with PD-1 inhibitors +/- chemotherapy (stage IV). Blood samples were collected pre-treatment, 2-4 weeks after treatment initiation and approximately 6-8 weeks thereafter until progression. Patients with a positive MRD test showed significantly worse PFS than those who tested negative (HR 4.8; 95% CI, 2.1-10.8; P < 0.0001). "Together, these two studies demonstrate the potential of Adela's tissue-agnostic test to predict outcomes and support clinical decision-making for patients receiving immunotherapy across a range of cancer types," said Dr. Anne-Renee Hartman, Chief Medical Officer at Adela. "Because tumor tissue is often unavailable in patients with advanced cancer, Adela's blood-only, tissue-free approach offers a universally accessible solution for this population." Adela's MRD test based on its genome-wide methylome enrichment platform is currently available to biopharmaceutical companies and other investigators for Research Use Only (RUO), including for biomarker discovery and drug development. Adela plans to commercialize the test in 2025 for use in patients who have received curative intent treatment for head & neck cancer, regardless of HPV status, to detect recurrence earlier and help guide treatment decision-making. Presentation Details Abstract #8550: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay Dr. Tuan Hoang1 Hall A, Poster Board: 30 Saturday May 31, 2025 1:30 PM-4:30 PM CDT Abstract # 2545: Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab DR. Enrique Sanz-Garcia1 Hall A, Poster Board: 192 Monday June 2, 2025 1:30 PM-4:30 PM CDT About Adela Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Adela's approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela's first product utilizing this genome-wide methylome enrichment platform was recently clinically validated for predicting and surveilling for recurrence in patients with head & neck cancer and published in Annals of Oncology. Adela's investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management and Labcorp. Find more information at 1 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada View original content to download multimedia: SOURCE Adela Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store